Jake June-Koo Lee, PhD, MD
Jake June-Koo Lee, PhD, MD
Research Fellow in Biomedical Informatics, Harvard Medical School
Mentor: Peter Park, PhD

Jake (June-Koo) Lee is a physician-scientist pursuing novel anticancer therapeutics based on his research experience in clinical oncology and cancer genomics.

Lee received his medical degree summa cum laude in 2008 from Seoul National University College of Medicine, South Korea. He did his internal medicine residency in Seoul National University Hospital from 2009 to 2013. During this time, he did clinical oncology research focusing on molecular targeted therapy in lung cancer. His meta-analysis of clinical trials provided clinical guidance on appropriate indication of EGFR tyrosine kinase inhibitors (Lee et al. 2014 JAMA; PMID 24715074), and he also designed and led the first investigator-initiated, phase II clinical trial of vandetanib in patients with lung adenocarcinoma harboring RET rearrangement (Lee et al. 2017 Ann Oncol; PMID 27803005).

Following his residency, Lee began translational cancer research at the Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST). There he pursued his academic interest in the histologic transformation process during EGFR tyrosine kinase inhibitor treatments, and explored the early-branched evolutionary history of small-cell transformed tumors (Lee et al. 2017 J Clin Oncol; in press). He also received his PhD in 2017.

Lee joined the Park lab in 2017 as a research fellow, and he is using large-scale whole-genome sequencing datasets to study the process by which genomic instability generates cancer driver mutations.

Detecting the mutational signature of homologous recombination deficiency in clinical samples.
Authors: Gulhan DC, Lee JJ, Melloni GEM, Cortés-Ciriano I, Park PJ.
Nat Genet
View full abstract on Pubmed
Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study.
Authors: Jung M, Kim S, Lee JK, Yoon SO, Park HS, Hong SW, Park WS, Kim JE, Kim J, Keam B, Kim HJ, Kang HJ, Kim DW, Jung KC, Kim YT, Heo DS, Kim TM, Jeon YK.
View full abstract on Pubmed
Human glioblastoma arises from subventricular zone cells with low-level driver mutations.
Authors: Lee JH, Lee JE, Kahng JY, Kim SH, Park JS, Yoon SJ, Um JY, Kim WK, Lee JK, Park J, Kim EH, Lee JH, Lee JH, Chung WS, Ju YS, Park SH, Chang JH, Kang SG, Lee JH.
View full abstract on Pubmed
Mutalisk: a web-based somatic MUTation AnaLyIS toolKit for genomic, transcriptional and epigenomic signatures.
Authors: Lee J, Lee AJ, Lee JK, Park J, Kwon Y, Park S, Chun H, Ju YS, Hong D.
Nucleic Acids Res
View full abstract on Pubmed
Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas.
Authors: Lee JK, Lee J, Kim S, Kim S, Youk J, Park S, An Y, Keam B, Kim DW, Heo DS, Kim YT, Kim JS, Kim SH, Lee JS, Lee SH, Park K, Ku JL, Jeon YK, Chung DH, Park PJ, Kim J, Kim TM, Ju YS.
J Clin Oncol
View full abstract on Pubmed
Complex chromosomal rearrangements by single catastrophic pathogenesis in NUT midline carcinoma.
Authors: Lee JK, Louzada S, An Y, Kim SY, Kim S, Youk J, Park S, Koo SH, Keam B, Jeon YK, Ku JL, Yang F, Kim TM, Ju YS.
Ann Oncol
View full abstract on Pubmed
Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial.
Authors: Lee SH, Lee JK, Ahn MJ, Kim DW, Sun JM, Keam B, Kim TM, Heo DS, Ahn JS, Choi YL, Min HS, Jeon YK, Park K.
Ann Oncol
View full abstract on Pubmed
Two recent phase 2 trials of vandetanib in RET-rearranged NSCLC.
Authors: Lee SH, Lee JK.
Lancet Respir Med
View full abstract on Pubmed
Mechanisms and Consequences of Cancer Genome Instability: Lessons from Genome Sequencing Studies.
Authors: Lee JK, Choi YL, Kwon M, Park PJ.
Annu Rev Pathol
View full abstract on Pubmed
Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation.
Authors: Kim MH, Kim J, Hong H, Lee SH, Lee JK, Jung E, Kim J.
View full abstract on Pubmed